Enitiatebio Nets One Hundred Million of CNY in Series A Round
Enitiatebio (Chinese: 启元生物) completed one hundred million of CNY （USD） in Series A financing round on August 31, 2022. This round was led by Momentum Venture (Chinese: 时节创投), followed by Taikun Fund (Chinese: 泰鲲基金), LPSCO (Chinese:临平国投) and Hangzhou Jintou Industrial Fund (Chinese:杭州金投产业基金). StartPointAdvisors (Chinese: 行远致同) acted as the exclusive financial advisor for this transaction.
Enitiatebio was co-founded by Viva Vision (Chinese: 维眸生物) and Betta Biomedical Industry Fund (Chinese: 贝达生物医药产业基金) at the end of 2020. The company was dedicated to developing innovative drugs for treating autoimmune diseases.
The competitors of the company include 3SBIONIC(Chinese: 三生制药), CarthroniX, and Angany.
Briefing Jan 30, 2023 10:44 AM
· Healthcare
Levostar Completes Pre-A Financing Round to Further Invest in CGT
Briefing Jan 18, 2023 10:59 AM
· Healthcare
BlissBio Nets Over CNY 100 Mn in Series B+
In-depth
Briefing Sep 21, 2022 10:38 AM
· Healthcare
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Briefing Sep 16, 2022 11:10 PM
· Healthcare
NaviSeed Nets Tens of millions of CNY in Angel Round
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Briefing Sep 13, 2022 05:30 PM
· Healthcare
Nuwacell Nets Hundreds of Mns of CNY in Series A
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Insight
Healthcare
Opportunities and Challenges Hidden in the CGT Industry in China
CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.
Jan 17, 2023 05:48 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
See more
Read next
Insight
In-depth
Insight
In-depth
Consumer Discretionary
GeerTop: China's Camping Market Growth Expected to Slow
Feb 02, 2023 12:01 PM
Insight
In-depth
Healthcare
Chinese Company Turned the Tables on Domestic Cell Culture Media Market
Feb 02, 2023 10:45 AM
Insight
In-depth